Rocket Pharmaceuticals Stock Forecast
NASDAQ: RCKTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
RCKT analyst consensus
Consensus (14 analysts)
buy
Avg. price target
$8.50+232.03%
- Strong buy 1
- Buy 6
- Hold 5
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 14 Wall Street analysts covering Rocket Pharmaceuticals (2026-10-08), 7 rate the stock a buy or strong buy, 5 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $8.50, with a high estimate of $15.00 and a low estimate of $2.95. The average target implies upside of 232.0% from the current price of $2.56.
The spread between the highest and lowest targets is 408.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RCKT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 6 | 43% |
| Hold | 5 | 36% |
| Sell | 1 | 7% |
| Strong sell | 1 | 7% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.95 | +15.23% |
| Average target | $8.50 | +232.03% |
| High target | $15.00 | +485.94% |